News | August 01, 2024
Strides Pharma posts Q1 FY25 PAT at Rs. 68.3 Cr
The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY
The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY
Dr. Agarwals Eye Hospital has reported total income of Rs. 100.42 crores during the period ended June 30, 2024
Ajanta Pharma has reported total income of Rs. 1,171.39 crores during the period ended June 30, 2024
The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
Fredun Pharmaceuticals has reported total income of Rs. 78.81 crores during the period ended June 30, 2024
Themis Medicare has reported total income of Rs. 123.95 crores during the period ended June 30, 2024
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
Granules India has reported total income of Rs. 1181.92 crores during the period ended June 30, 2024
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
Subscribe To Our Newsletter & Stay Updated
